Zhang Jiudan, Chen Ye, Wang Jian, Xia Hong, Zheng Yang
Department of Endocrinology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Department of Internal Medicine, Nanjing Municipal Center for Prevention and Treatment of Occupational Disease, Nanjing, China.
Nagoya J Med Sci. 2021 May;83(2):343-351. doi: 10.18999/nagjms.83.2.343.
Glucocorticoid use may trigger secondary diabetes or exacerbate hyperglycemia in patients with diabetes mellitus (DM). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of patients with type 2 diabetes. Few reports mention liraglutide as a treatment for steroid-induced DM (SIDM). Here, we report a patient with SIDM and multiple sclerosis, for whom switching to liraglutide combined with metformin therapy improved glucose levels and ameliorated the symptoms of insulin allergy. Liraglutide may be useful for treating SIDM with insulin allergy.
使用糖皮质激素可能会引发继发性糖尿病，或使糖尿病（DM）患者的高血糖状况恶化。利拉鲁肽是一种用于治疗2型糖尿病患者的胰高血糖素样肽-1（GLP-1）受体激动剂。很少有报告提及将利拉鲁肽用于治疗类固醇诱导的糖尿病（SIDM）。在此，我们报告了一名患有SIDM和多发性硬化症的患者，改用利拉鲁肽联合二甲双胍治疗改善了其血糖水平，并缓解了胰岛素过敏症状。利拉鲁肽可能对治疗伴有胰岛素过敏的SIDM有用。
